FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912402729> ?p ?o ?g. }

• W2912402729 endingPage "114" @default.
• W2912402729 startingPage "106" @default.
• W2912402729 abstract "Methotrexate (MTX) is a major systemic treatment for moderate to severe plaque psoriasis. A randomized trial has recently been published evaluating a single weekly dosage (17.5mg), but few prospective real-life data are available. The main objective of this study was to prospectively evaluate the efficacy of MTX in real-life. The secondary objectives were to evaluate predictive parameters for treatment efficacy and the frequency of adverse events.A prospective cohort involving consecutive at in 25 centres belonging to GEM RESOPSO included all adults with plaque psoriasis in whom MTX treatment was initiated. The efficacy criterion was achievement of PASI 75 at week (W) 12/16. The impact of demographic data, psoriasis characteristics (duration, topography, rheumatism), dosage (W12/16 dosage, cumulative dose after 4 weeks), and mode of administration (subcutaneous vs. oral, concomitant use of folic acid) on efficacy was evaluated. Intention-to-treat (ITT),per protocol (PP), and multivariate analyses were performed.Two hundred and fifty-six patients (F/M: 105/151; mean age: 45.0 years; rheumatism: 12.6%) with plaque psoriasis were included. 99 patients were not analysed at W12/16 (16 because of inefficacy, 16 because of intolerance, 56 were lost to follow-up or had data missing). PASI 75 was achieved in 98 patients, with efficacy of 38.3% in the ITT analysis and 58.3% in the PP analysis. In the ITT analysis, absence of previous use of cyclosporine (P=0.01) and a cumulative dose of MTX>60mg after 4 weeks (P<0.0001) were associated with higher PASI 75 rates. In the PP analysis, only absence of previous use of cyclosporine (P=0.0009) was associated with a better PASI 75 results. There was no association between PASI 75 and patient characteristics (including body mass index), clinical aspects of psoriasis, route of administration, combination with folic acid, or W12/16 dose. Adverse events were reported by 34.8% of patients. These consisted mainly of digestive disorders (nausea, abdominal pain), asthenia and moderate hepatic cytolysis. The frequency of adverse events was correlated with methotrexate dosage.The efficacy of MTX in plaque psoriasis in this real-life study of 256 patients is consistent with the data in the literature, including the recently published randomized trial (41% PASI 75). This rate was unaffected by patient weight, route of administration and combined use of folic acid. Absence of previous use of cyclosporine appears to be associated with better efficacy although there is no clear explanation for this. The initial dosage (high dose in the first month) appears to be associated with superior efficacy for W12/W16." @default.
• W2912402729 created "2019-02-21" @default.
• W2912402729 creator A5000349002 @default.
• W2912402729 creator A5002573974 @default.
• W2912402729 creator A5004079103 @default.
• W2912402729 creator A5007427635 @default.
• W2912402729 creator A5022555578 @default.
• W2912402729 creator A5026304493 @default.
• W2912402729 creator A5028528715 @default.
• W2912402729 creator A5040970287 @default.
• W2912402729 creator A5071851101 @default.
• W2912402729 creator A5072137871 @default.
• W2912402729 creator A5073653626 @default.
• W2912402729 creator A5077223887 @default.
• W2912402729 creator A5077954088 @default.
• W2912402729 creator A5081205053 @default.
• W2912402729 creator A5081924094 @default.
• W2912402729 creator A5083025557 @default.
• W2912402729 creator A5084274240 @default.
• W2912402729 date "2019-02-01" @default.
• W2912402729 modified "2023-10-16" @default.
• W2912402729 title "Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France" @default.
• W2912402729 cites W1581115144 @default.
• W2912402729 cites W1972597833 @default.
• W2912402729 cites W2069350424 @default.
• W2912402729 cites W2104883144 @default.
• W2912402729 cites W2321934992 @default.
• W2912402729 cites W2322894603 @default.
• W2912402729 cites W2366994925 @default.
• W2912402729 cites W2521108778 @default.
• W2912402729 cites W2564524674 @default.
• W2912402729 cites W2565351134 @default.
• W2912402729 cites W2577147615 @default.
• W2912402729 cites W2594245371 @default.
• W2912402729 cites W2626009639 @default.
• W2912402729 cites W2756408557 @default.
• W2912402729 cites W2792715494 @default.
• W2912402729 cites W4211077900 @default.
• W2912402729 cites W4236468298 @default.
• W2912402729 cites W4248269869 @default.
• W2912402729 cites W4376849728 @default.
• W2912402729 doi "https://doi.org/10.1016/j.annder.2018.11.011" @default.
• W2912402729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30704943" @default.
• W2912402729 hasPublicationYear "2019" @default.
• W2912402729 type Work @default.
• W2912402729 sameAs 2912402729 @default.
• W2912402729 citedByCount "9" @default.
• W2912402729 countsByYear W29124027292019 @default.
• W2912402729 countsByYear W29124027292020 @default.
• W2912402729 countsByYear W29124027292021 @default.
• W2912402729 countsByYear W29124027292022 @default.
• W2912402729 countsByYear W29124027292023 @default.
• W2912402729 crossrefType "journal-article" @default.
• W2912402729 hasAuthorship W2912402729A5000349002 @default.
• W2912402729 hasAuthorship W2912402729A5002573974 @default.
• W2912402729 hasAuthorship W2912402729A5004079103 @default.
• W2912402729 hasAuthorship W2912402729A5007427635 @default.
• W2912402729 hasAuthorship W2912402729A5022555578 @default.
• W2912402729 hasAuthorship W2912402729A5026304493 @default.
• W2912402729 hasAuthorship W2912402729A5028528715 @default.
• W2912402729 hasAuthorship W2912402729A5040970287 @default.
• W2912402729 hasAuthorship W2912402729A5071851101 @default.
• W2912402729 hasAuthorship W2912402729A5072137871 @default.
• W2912402729 hasAuthorship W2912402729A5073653626 @default.
• W2912402729 hasAuthorship W2912402729A5077223887 @default.
• W2912402729 hasAuthorship W2912402729A5077954088 @default.
• W2912402729 hasAuthorship W2912402729A5081205053 @default.
• W2912402729 hasAuthorship W2912402729A5081924094 @default.
• W2912402729 hasAuthorship W2912402729A5083025557 @default.
• W2912402729 hasAuthorship W2912402729A5084274240 @default.
• W2912402729 hasConcept C126322002 @default.
• W2912402729 hasConcept C141071460 @default.
• W2912402729 hasConcept C151032500 @default.
• W2912402729 hasConcept C16005928 @default.
• W2912402729 hasConcept C188816634 @default.
• W2912402729 hasConcept C197934379 @default.
• W2912402729 hasConcept C2777011040 @default.
• W2912402729 hasConcept C2777489490 @default.
• W2912402729 hasConcept C2779384505 @default.
• W2912402729 hasConcept C2780564577 @default.
• W2912402729 hasConcept C2781059491 @default.
• W2912402729 hasConcept C71924100 @default.
• W2912402729 hasConcept C90924648 @default.
• W2912402729 hasConceptScore W2912402729C126322002 @default.
• W2912402729 hasConceptScore W2912402729C141071460 @default.
• W2912402729 hasConceptScore W2912402729C151032500 @default.
• W2912402729 hasConceptScore W2912402729C16005928 @default.
• W2912402729 hasConceptScore W2912402729C188816634 @default.
• W2912402729 hasConceptScore W2912402729C197934379 @default.
• W2912402729 hasConceptScore W2912402729C2777011040 @default.
• W2912402729 hasConceptScore W2912402729C2777489490 @default.
• W2912402729 hasConceptScore W2912402729C2779384505 @default.
• W2912402729 hasConceptScore W2912402729C2780564577 @default.
• W2912402729 hasConceptScore W2912402729C2781059491 @default.
• W2912402729 hasConceptScore W2912402729C71924100 @default.
• W2912402729 hasConceptScore W2912402729C90924648 @default.
• W2912402729 hasIssue "2" @default.
• W2912402729 hasLocation W29124027291 @default.

• next